Related references
Note: Only part of the references are listed.Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)
Javier Martin-Lopez et al.
JOURNAL OF CLINICAL PATHOLOGY (2023)
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
Esther Conde et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?
Ullas Batra et al.
JOURNAL OF CLINICAL PATHOLOGY (2022)
Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System
Maisam Makarem et al.
CURRENT ONCOLOGY (2021)
ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm
Yuanyuan Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
Xingya Ruan et al.
ONCOLOGY LETTERS (2020)
Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
Luciene Schluckebier et al.
BMC CANCER (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Detection of ALK and ROS1 rearrangements by immunocytochemistry on cytological samples
Diane Frankel et al.
ANNALES DE PATHOLOGIE (2019)
Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis
Ruiying Zhao et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid
Diane Frankel et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A. Kron et al.
ANNALS OF ONCOLOGY (2018)
Cytology Smears as Excellent Starting Material for Next-Generation Sequencing-Based Molecular Testing of Patients With Adenocarcinoma of the Lung
Nadezda P. Velizheva et al.
CANCER CYTOPATHOLOGY (2017)
Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing
Gou Yamamoto et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
ALK and ROS1 Testing on Lung Cancer Cytologic Samples: Perspectives
Pasquale Pisapia et al.
CANCER CYTOPATHOLOGY (2017)
Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma
Jordan E. Baum et al.
CANCER CYTOPATHOLOGY (2017)
Preanalytic Variables in Cytology Lessons Learned From Next-Generation Sequencing-The MD Anderson Experience
Sinchita Roy-Chowdhuri et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
ALK Protein Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
Antonio Marchetti et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
ALK and ROS1 Rearrangements Tested by Fluorescence In Situ Hybridization in Cytological Smears From Advanced Non-Small Cell Lung Cancer Patients
Cecilia Bozzetti et al.
DIAGNOSTIC CYTOPATHOLOGY (2015)
Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
Toni-Maree Rogers et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations
Yen-Fu Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
ROS1 fusions in Chinese patients with non-small-cell lung cancer
W. Cai et al.
ANNALS OF ONCOLOGY (2013)
Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer
Koichi Hagiwara et al.
CANCER SCIENCE (2013)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
Marta Salido et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Share Paper
